ProMIS Reports First Human Evidence Of Target Engagement For Alzheimer's Drug PMN310

ProMIS Neurosciences said its Alzheimer’s lead candidate PMN310 showed the first human evidence of a dose-dependent reduction in amyloid-beta oligomers, a toxic protein form implicated in the disease. The update is a meaningful early clinical signal, but it does not yet quantify full efficacy outcomes. Overall, this supports a cautiously positive outlook for the program.

Analysis

ProMIS Neurosciences said its Alzheimer’s lead candidate PMN310 showed the first human evidence of a dose-dependent reduction in amyloid-beta oligomers, a toxic protein form implicated in the disease. The update is a meaningful early clinical signal, but it does not yet quantify full efficacy outcomes. Overall, this supports a cautiously positive outlook for the program.